Review Article

Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis

Ling Chen, Xiwei Wang, Qiongfang Zhang, Jiaojiao Gong, Shasha Shen, Wenwei Yin, and Huaidong Hu

Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Second Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

Correspondence should be addressed to Huaidong Hu; hhd0126@163.com

Received 31 August 2015; Revised 13 October 2015; Accepted 20 October 2015

Academic Editor: Hubert E. Blum

Copyright © 2016 Ling Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background/Aims. It remains unclear whether tenofovir disoproxil fumarate- (TDF-) based combination therapy produces better outcomes than TDF monotherapy in chronic hepatitis B (CHB) patients. The aim of this study was to compare the efficacy of the two regimens by performing a meta-analysis. Methods. A comprehensive literature search was performed on the comparison of TDF-based combination therapy and monotherapy for CHB patients in the PubMed, Embase, Web of Science, and the Cochrane Libraries. Both dichotomous and continuous variables were extracted and pooled outcomes were expressed as risk ratio (RR) or standard mean difference (SMD). Results. Nine eligible studies (1089 subjects in total) were included in our analysis. The proportion of patients with undetectable HBV DNA at 24, 48, and 96 weeks were similar between the two comparable groups (62.5% versus 70.9%, \( P = 0.086 \); 78.1% versus 83.7%, \( P = 0.118 \); 86.4% versus 87.9%, \( P = 0.626 \), resp.). HBV DNA reduction, rates of ALT normalization, hepatitis B e antigen (HBeAg) loss, and HBeAg seroconversion were also similar between the two groups.

Conclusions. On the current data, TDF-based combination therapy seemed to be no better than those achieved by monotherapy. Further studies are needed to verify this comparison.

1. Introduction

Hepatitis B virus (HBV) infection is a worldwide healthcare problem and HBV virions cannot be cleared completely because the covalently closed circular DNA persists in the nuclei of infected hepatocytes. Hence, the main purpose of antiviral therapy is sustained viral suppression. Guidelines recommend sustained viral suppression as the most effective way to reduce complications and improve quality of life [1]. Antiviral therapy with nucleos(t)ide analogues (NAs) is now the frontline treatment for chronic hepatitis B (CHB) patients because of its demonstrably suppressive effects on viruses. However, NAs must be administered for extended periods due to the high frequency of virological relapse following the discontinuation of treatment, but long-term use of NAs can result in drug resistance and toxicity [2, 3]. Therefore, optimal antiviral treatments with a high genetic barrier to resistance, good safety, and durable efficacy should be deployed [4].

Currently, TDF is a potent inhibitor of HBV replication with a high genetic barrier to resistance among both treatment-naive and NAs-experienced CHB patients [5, 6]. Even though other NAs are effective in lowering HBV DNA levels and improving prognosis after long-term treatment, treatment resistance has been reported in 70% of patients after four years of lamivudine (LAM) treatment, 29% of HBV e antigen- (HBeAg-) negative patients after five years of Adefovir dipivoxil (ADV) treatment, 25% of HBeAg-negative patients after two years of telbivudine (LdT) treatment, and 1.2% of patients after five years of entecavir (ETV) treatment [7–10]. Conversely, there has been no associated
resistance observed after three years of TDF treatment [6].
In addition, treatment with TDF for up to six years leads to
a significant decrease in hepatitis B surface antigen (HBsAg)
in the HBeAg-positive population with HBV/HIV coinfection:
cumulative rates of HBsAg seroclearance were 8% in these cases; such high rates of HBsAg seroclearance are not
achieved by other NAs [11].

TDF monotherapy is effective for patients with viral
breakthrough or having suboptimal responses to previous
NA treatment, but TDF-based combination therapy should
be considered in patients with drug resistance because of
a further decrease in HBV DNA following the addition of
another NA [12]. However, it remains a subject of con-
troversy whether TDF-based combination therapy induces
better outcomes than TDF monotherapy in NA-experienced
patients with previous treatment failures. No relevant meta-
analyses have directly compared the two treatment strategies.
Thus, our meta-analysis aimed to do so, comparing the
relative efficacy of TDF-based combination therapy and
TDF monotherapy in CHB patients with previous treatment failures.

2. Methods

2.1. Literature Search. Relevant studies regarding the compar-
tison of TDF-based combination therapy and TDF monother-
apy for CHB patients were identified by searching the
PubMed, Embase, Web of Science, and the Cochrane
Libraries, using the medical subject headings “tenofovir”,
“chronic hepatitis B”, “monotherapy”, “combination ther-
apy”, “nucleoside analog”, “nucleotide analog”, and their abbreviations. Multiple synonyms were also used. The search was
restricted to “human” and “English”. The reference lists
of all the retrieved documents were manually searched for
potentially relevant reports missed by the intelligent retrieval systems mentioned above. The search was carried out in
March, 2015, and the entire selection process was completed
independently by two investigators (LC and XWW). Incon-
sistent search results were resolved with the assistance of an
arbiter (HDH) when necessary.

2.2. Selection Criteria. Inclusion criteria for the meta-analysis
were as follows: (a) randomized controlled trials (RCTs), ret-
spective and prospective cohort study designs; (b) patients
with CHB (defined as a positive serum HBsAg test for at least
6 months) having previously received any NA other than TDF
and presenting with a suboptimal response to the prior NA
treatment; (c) studies comparing TDF-based combination
therapy and TDF monotherapy for previously treated HBV
with a course of therapy equal to or more than 48 weeks; and
(d) studies providing information that included, at minimum,
virological response (HBV DNA levels), serological response
(HBeAg and HBsAg loss or seroconversion), or biochemical
response (ALT normalization). Studies were excluded
if they featured (a) noncomparative data or observational
methodologies, (b) no available outcome measures and a
therapy course of less than 48 weeks, (c) coinfection with
hepatitis A, hepatitis C, hepatitis D, or hepatitis E viruses or
human immune-deficiency virus (HIV), and (d) definitive
diagnosis with HCC or a history of renal failure and organ
transplantation.

2.3. Outcome Measures. The rates of virological response,
biochemical response, and serological response were used as
primary efficacy measures. “Virological response” included
virological suppression defined as achievement of unde-
tectable HBV DNA levels to below the detection level
and HBV DNA levels that changed over time. “Biochemical
response” included ALT normalization, defined as the pro-
portion of subjects with normal ALT levels after treatment,
where patients had had abnormal ALT levels at baseline.
“Serological response” included rates of HBeAg loss, HBeAg
seroconversion, HBsAg loss, and HBsAg seroconversion. The
adverse effects (AEs) caused by study drugs also received
special attention.

2.4. Data Extraction. All data were independently extracted
from the included studies by two investigators (LC and
XWW) and, where possible, calculated and checked twice.
Any dispute between investigators was resolved by discussion
or arbitration (by HDH) when necessary. If useful data were
presented indirectly by figures or graphs, they were translated
into correlative patterns by using Get-Data software or
relevant formulae when there was no response from authors.
If mean values or standard deviation (SD) for analysis was
unavailable, they were calculated from medians and ranges
using relevant formulae [13]. The following information
was extracted: year of publication, study design, race of
participants, number of patients per study group, patient
clinical characteristics at baseline, treatment regimen and
course received, and interesting endpoints.

2.5. Study Quality. The quality of all included RCTs was
assessed using the revised Jadad quality scale, which graded
the quality of a study from 0 (lowest) to 7 (highest) by
examining randomization, blinding, allocation concealment,
and drop-out. For cohort designs, the quality was assessed
using the Newcastle-Ottawa Scale (NOS) based on several
standards including selection of cohorts, comparability of
cohorts, and assessment of the outcomes.

2.6. Statistical Analysis. Data analysis was carried out with
software Stata version 12.0 (Stata Corporation, College Sta-
tion, TX, USA) and was based on an intent-to-treat principle.
Both dichotomous and continuous variables were extracted
in this analysis. Outcomes were expressed as RR, or SMD
with 95% confidence intervals (CI). The overall effects were
measured using a Z-score with a significance set at P < 0.05.
Statistical heterogeneity was evaluated by using chi-
square and I-square (I²) tests with a significance set at
P < 0.1. P < 0.1 and I² > 50% were considered to
be significant heterogeneity. The random-effect method was
used to combine results if confirmed significant heterogeneity
was observed; otherwise, the fixed-effect method was used.
To assess sources of potential bias, sensitivity analyses were
performed where required. The publication bias of selected
articles was assessed by funnel plots and any potential bias
was judged by Begg’s and Egger’s tests.
3. Results

3.1. Search Results. The search strategy resulted in the identification of 1187 records in total. 265 records were duplicate documents retrieved from two or more databases and thus removed. The remaining studies received further screening by scanning the title or abstract, which resulted in the exclusion of a further 903 studies. As a result, 19 full-text articles were subjected to detailed evaluation, of which two were excluded because they analyzed the same patient groups, and a further eight were excluded due to lack of available data. Eventually, nine eligible articles relating to a total of 1089 subjects (592 in combination therapy groups and 497 in monotherapy groups) were chosen for this meta-analysis (Figure 1).

Of the nine eligible studies, five were RCTs [14–18] and four were cohorts [19–22]. All of the five RCTs receiving a Jadad score of at least 5 were considered of relatively high quality and all of the four cohort studies received NOS score of at least 5 (Supplementary Table 1 in Supplementary Material available online at http://dx.doi.org/10.1155/2015/7214020). The detailed characteristics of the included studies are summarized in Table 1. For those endpoints with more than five included articles, we performed analysis of publication bias. Publication bias was not found in any outcome measure (Supplementary Figure 1).

3.2. Virological Responses. Rates of undetectable HBV DNA were similar between TDF monotherapy and combination therapy at 24, 48, and 96 weeks (62.5% versus 70.9%, \( P = 0.086 \); 78.1% versus 83.7%, \( P = 0.118 \); 86.4% versus 87.9%, \( P = 0.626 \), resp.) (Figure 2). Six studies with a total of 583 patients reported a change of serum HBV DNA levels at 48 weeks from baseline and no superior efficacy was demonstrated in TDF-based combination therapy when compared to monotherapy (\( P = 0.459 \)) (Supplementary Figure 2).

3.3. Serological Response. Among HBeAg-positive patients, data for HBsAg loss and seroconversion analysis were extracted and a fixed-effect model showed that a similar proportion in each treatment group experienced HBsAg loss (16.4% versus 14.1%, \( P = 0.194 \)) and seroconversion to anti-HBe (9.2% versus 7.7%, \( P = 0.606 \)) during the study period (Figure 3). Three patients (two in TDF monotherapy groups and one in TDF-based combination therapy groups) were reported to have achieved HBsAg seroclearance but only one of these obtained seroconversion to anti-HBs.

3.4. Biochemical Response. Among those patients with abnormal ALT levels at baseline, data about ALT normalization were extracted and a fixed-effect model showed that a similar proportion of patients in the two groups experienced ALT normalization at each time point (44.4% versus 50.4%, \( P = 0.580 \) for 48 weeks; 74.6% versus 68.4%, \( P = 0.614 \) for 96 weeks) (Figure 4).

3.5. Safety. Berg et al. [14] reported that, in the combination group, one patient suffered from severe study drug-related AE with an increase of ALT from 80 U/L at baseline to 432 U/L at week 8. Fung et al. [16] reported that three patients (two in monotherapy group and one in combination group) experienced study drug discontinuation for AEs, of which one was judged to be caused by the study drug. Liaw et al. [15] reported that six patients dropped out of the study because of AEs but none of these AEs was considered to be related to study drug. Out of all included patients, six patients developed HCC and six patients experienced bone fracture, but none of these cases was considered to be study treatment related.

4. Discussion

Even though TDF exhibited effective and safe outcomes in patients with previously multiple NA treatment failures [23], HBV DNA decline was slower in NA-experienced patients than in treatment-naive patients after TDF therapy; optimal TDF-based combination treatment should thus be considered in NA-experienced patients [24]. TDF-emtricitabine (FTC) combination therapy resulted in undetectable HBV DNA levels without any renal toxicity for those with detectable HBV DNA on ADV [25]. Rescue therapy with TDF-ETV combination was efficient and safe in patients with multidrug-resistant (MDR) HBV strains regardless of the antiviral drug resistance profiles [26]. LdT therapy with TDF intensification in HBeAg-positive CHB patients at week 24 appeared effective and well tolerated [27]. Both TDF monotherapy and combination therapy can effectively inhibit the virus and show good levels of tolerability in NA-experienced patients, but which one can produce better outcomes is still uncertain. Therefore, we performed a meta-analysis including studies that involved the comparison between TDF-based combination therapy and monotherapy, to investigate the uncertainty.

Despite the fact that TDF-based combination therapy is reported to provide more effective HBV suppression than therapy with each drug alone in vitro and in a robust mouse model [28], the results of our meta-analysis suggest that viral suppression occurring in monotherapy groups seemed to be similar to that in combination therapy groups (62.5% versus 70.9%, \( P = 0.086 \) at 24 weeks; 78.1% versus 83.7%, \( P = 0.118 \) at 48 weeks; 86.4% versus 87.9%, \( P = 0.626 \) at 96 weeks). Rates of undetectable HBV DNA were all higher in TDF combination therapy groups at the three time points but none of the three time points achieved statistical significance. According to these data, we can find that the difference of the rates of undetectable HBV DNA between the two regimens was gradually narrowing with the follow-up time extending. The reason for this tendency may be primarily due to the gradual emergence of resistance induced by study drug that TDF combined with in combination therapy groups.

Even though significance was not achieved, our meta-analysis demonstrated that combination therapy tended to lead to less HBeAg loss, and this was contrary to the result of undetectable HBV DNA, for which the reason may be that combination groups contained more HBeAg-positive patients than those that monotherapy groups included at baseline (as shown in Table 1), thereby resulting in lower
Records identified from databases \((n = 1187)\)

Records after duplicates removed \((n = 922)\)

Records excluded due to absolutely unrelated titles \((n = 645)\)

Abstracts read for further screening \((n = 277)\)

Full-text articles retrieved for detailed evaluation \((n = 19)\)

Full-text articles excluded for the following:
- Analysis for the same patient groups \((n = 2)\)
- No available data \((n = 8)\)

Studies left for the meta-analysis \((n = 9)\)

**Figure 1:** Flow diagram of literature selection process.

HBeAg loss rates in combination groups in the case that the absolute numbers of HBeAg loss during study were not much different between the two comparative groups. Only three patients were reported to have HBsAg loss, a number far below that reported by Zoutendijk et al. in the HBeAg-positive population where HBV/HIV coinfection received treatment of TDF for up to 6 years [11]. In our study, of the included patients, all were HBV monoinfected and only a portion were HBeAg-positive. Additionally, the longest duration of TDF treatment reported in the studies included in our analysis was 3 years, which is far shorter than 6 years; these may be the reasons for the low HBsAg loss rate in our meta-analysis.

Drug safety and resistance should be seriously considered when switching to new therapeutics in patients who have experienced pretreatment failures. After up to 144 weeks of exposure to TDF monotherapy, no NA-experienced patient developed HBV pol/RT mutations associated with TDF resistance, and a favorable safety profile was maintained in CHB patients [6, 29]. Although renal toxicity is associated with TDF in HIV-infected patients, renal dysfunction was rarely reported in CHB patients [30]. TDF-based combination therapy also had a good safety profile in CHB patients after a median follow-up of >76 weeks [31]. In our meta-analysis, no included studies reported resistance mutations related to TDF management, and virological breakthrough rarely happened in either treatment group. Most study drug-related AEs were gentle and rarely resulted in discontinuation of treatment (only two instances were reported). Berg et al. [14] reported no statistically significant difference in any AE parameter including study drug-related AEs between TDF monotherapy and combination therapy at 48 weeks, with Fung et al. [16] and Yoo et al. [18] reporting similar results at 96 weeks. These results revealed that TDF therapy was well tolerated and safe for NA-experienced patients, while TDF-based combination therapy seemed not to increase the risk of AEs when compared with TDF monotherapy. TDF-based combination therapy resulted in lower adherence to antiviral treatment and higher costs for CHB patients [32], so monotherapy seems to be the optimal choice when patients need to switch to TDF treatment. However, our analysis only covered the period up to 96 weeks; for those patients who need to receive antiviral treatments for a longer time, comparisons of efficacy and safety between TDF-based combination and monotherapy should be conducted using larger and lengthier clinical trials.

Confirmed heterogeneity was found in two endpoints: 48-week HBV DNA reduction \((P = 0.025, I^2 = 61.1\%)\) and 96-week virological suppression \((P = 0.097, I^2 = 63.7\%)\). Sensitivity analysis was performed to find the source of heterogeneity in the endpoint of HBV DNA reduction. When the study reported by Lee et al. was excluded, the pooled
## Table 1: Characteristics of studies included in the meta-analysis.

| Study          | Centers | Design | N   | Age (year) | Sex (M/F) | Positive HBeAg (N) | HBV DNA (log 10 copies/mL) | Regimen                     | Therapy duration (week) | Treatment experience | Resistant mutations                  |
|----------------|---------|--------|-----|------------|-----------|-------------------|----------------------------|-----------------------------|-------------------------|-----------------------|---------------------------------------|
| Berg et al. [14] | Multi   | RCT    | M: 53 | 40 ± 11.4  | 38/15     | 38                | 6.06 ± 1.43               | TDF 300 mg/d                | 48                     | LAM, ADV               | rtM204V/I, rtL180M, rtV173L, rtN236T, rtA181V/T |
|                |         |        | C: 52 | 39 ± 10.4  | 42/10     | 39                | 5.87 ± 1.78               | TDF 300 mg/d; FTC 200 mg/d |                        |                       |                                       |
| Liaw et al. [15] | Multi   | RCT    | M: 45 | 52 ± 2.3   | 37/8      | 19                | 5.7 ± 0.43                | TDF 300 mg/d                | 48                     | LAM, ADV               | rtM204V/I, rtL180M          |
|                |         |        | C: 45 | 50 ± 4     | 40/5      | 23                | 6.28 ± 0.7                | TDF 300 mg/d; FTC 200 mg/d |                        |                       |                                       |
| Seto et al. [19] | Single  | Cohort | M: 71 | NA         | NA        | NA                | NA                         | TDF 300 mg/d                | 144                    | LAM, LdT, ETV, ADV       | rtA181V/T, rtN236T, rtA194T     |
|                |         |        | C: 54 | NA         | NA        | NA                | NA                         | TDF 300 mg/d; FTC 300 mg/d; LAM 300 mg/d |                        |                       |                                       |
| Lee et al. [22] | Single  | Cohort | M: 33 | 54 ± 10.8  | 22/11     | 16                | 2.83 ± 1.62               | TDF 300 mg/d                | 48                     | LAM, ADV               | rtM204V/I, rtL180M          |
|                |         |        | C: 120| 54 ± 8.3   | 84/36     | 80                | 2.77 ± 1.09               | TDF 300 mg/d; FTC 300 mg/d; LAM 300 mg/d |                        |                       |                                       |
| Fung et al. [16] | Multi   | RCT    | M: 141| 47.1 ± 13.6| 104/37    | 65                | 5.64 ± 1.83               | TDF 300 mg/d                | 96                     | LAM                   | rtM204V/I, rtL180M          |
|                |         |        | C: 139| 46.3 ± 13.6| 107/32    | 68                | 5.77 ± 1.97               | TDF 300 mg/d; FTC 200 mg/d |                        |                       |                                       |
| Lu et al. [20]  | Multi   | Cohort | M: 25 | 40 ± 14    | 16/9      | 22                | 3.10 ± 0.95               | TDF 300 mg/d; FTC 300 mg/d; LAM 300 mg/d | 48                     | ETV                   | NA                      |
|                |         |        | C: 43 | 40 ± 10.8  | 27/16     | 41                | 3.57 ± 0.90               | TDF 300 mg/d; FTC 1 mg/d   |                        |                       |                                       |
| Choi et al. [21] | Single  | Cohort | M: 34 | 48 ± 8     | 23/11     | 26                | 4.76 ± 1.7                | TDF 300 mg/d                | 48                     | LAM, LdT, ETV, ADV       | rtM204V/I, rtL180M, rt81A, rt236T, rtT184, rtN169, rtS202 |
|                |         |        | C: 42 | 50 ± 13    | 33/9      | 36                | 4.54 ± 1.76               | TDF 300 mg/d; FTC 300 mg/d; ETV 1 mg/d |                        |                       |                                       |
| Lim et al. [17] | Single  | RCT    | M: 45 | 51 ± 9     | 32/13     | 40                | 4.09 ± 0.6                | TDF 300 mg/d                | 48                     | LAM, LdT, ETV, ADV       | rtM204V/I, rtL180M, rt236T, rtT184, rtN169T, rtS202G, rtM250I/V |
|                |         |        | C: 45 | 52 ± 10    | 36/9      | 40                | 3.74 ± 0.46               | TDF 300 mg/d; FTC 1 mg/d   |                        |                       |                                       |
| Yoo et al. [18] | Single  | RCT    | M: 50 | 49 ± 10    | 42/8      | 44                | 3.27 ± 1.8                | TDF 300 mg/d                | 96                     | LAM, LdT, ETV, ADV       | rtM204V/I, rtL180M, rtA181T/V, rtN236T, rtT184, rtS202G, rtM250I/V, rtM204V/I |
|                |         |        | C: 52 | 50 ± 11    | 46/6      | 46                | 3.50 ± 1.69               | TDF 300 mg/d; FTC 1 mg/d   |                        |                       |                                       |

M: monotherapy group; C: combination therapy group; TDF: tenofovir disoproxil fumarate; FTC: emtricitabine; LAM: lamivudine; ETV: entecavir; ADV: adefovir dipivoxil; LdT: telbivudine; RCT: randomized controlled trial; and NA: not available.
| Study            | RR (95% CI)      | Weight (%) |
|------------------|------------------|------------|
| Lee et al., 2014 | 0.97 (0.77, 1.22) | 14.60      |
| Liaw et al., 2011| 0.91 (0.69, 1.19) | 12.41      |
| Fung et al., 2014| 0.60 (0.42, 0.87) | 14.52      |
| Seto et al., 2013| 1.03 (0.87, 1.21) | 34.84      |
| Berg et al., 2010| 0.95 (0.83, 1.01) | 100.00     |
| Overall (I² = 33.9%, P = 0.182) | 0.92 (0.83, 1.01) | 100.00     |
| Overall effect: Z = 1.72 (P = 0.086) |  |  |

![Favours combination therapy](a)

| Study            | RR (95% CI)      | Weight (%) |
|------------------|------------------|------------|
| Lee et al., 2014 | 0.95 (0.82, 1.11) | 8.95       |
| Liaw et al., 2011| 0.80 (0.64, 1.00) | 8.98       |
| Fung et al., 2014| 0.95 (0.86, 1.06) | 28.65      |
| Seto et al., 2013| 0.85 (0.68, 1.07) | 11.23      |
| Berg et al., 2010| 1.00 (0.83, 1.21) | 10.22      |
| Overall (I² = 9.8%, P = 0.353) | 0.95 (0.90, 1.01) | 100.00     |
| Overall effect: Z = 1.56 (P = 0.118) |  |  |

![Favours combination therapy](b)

| Study            | RR (95% CI)      | Weight (%) |
|------------------|------------------|------------|
| Fung et al., 2014| 1.03 (0.94, 1.13) | 58.27      |
| Seto et al., 2013| 0.88 (0.76, 1.03) | 41.73      |
| Overall (I² = 63.7%, P = 0.097) | 0.96 (0.83, 1.12) | 100.00     |
| Overall effect: Z = 0.49 (P = 0.626) |  |  |

Note: weights are from random effects analysis

![Favours combination therapy](c)

**Figure 2**: Forest map of summary estimates for comparison of virological suppression between TDF-based combination therapy and monotherapy groups. (a) 24 weeks; (b) 48 weeks; (c) 96 weeks.
| Study            | RR (95% CI)     | Weight (%) |
|-----------------|-----------------|------------|
| Berg et al., 2010 | 1.03 (0.22, 4.77) | 10.30      |
| Liaw et al., 2011 | 0.80 (0.22, 2.97) | 13.43      |
| Lee et al., 2014  | 1.62 (0.64, 4.09) | 14.61      |
| Fung et al., 2014 | 1.16 (0.50, 2.68) | 30.59      |
| Lim et al., 2015  | 1.00 (0.35, 2.84) | 20.87      |
| Yoo et al., 2015  | 3.14 (0.91, 10.83)| 10.20      |

Overall ($I^2 = 0.0\%, P = 0.687$)

Overall effect: $Z = 1.30 (P = 0.194)$

---

| Study            | RR (95% CI)     | Weight (%) |
|-----------------|-----------------|------------|
| Liaw et al., 2011 | 1.61 (0.31, 8.24) | 15.14      |
| Fung et al., 2014 | 1.05 (0.39, 2.82) | 53.66      |
| Lim et al., 2015  | 0.33 (0.04, 3.07) | 23.53      |
| Yoo et al., 2015  | 4.18 (0.49, 35.97)| 7.67       |

Overall ($I^2 = 0.0\%, P = 0.429$)

Overall effect: $Z = 0.52 (P = 0.606)$

---

**Figure 3**: Forest map of summary estimates for comparison of the changes in HBeAg between TDF-based combination therapy and monotherapy groups. (a) HBe loss; (b) HBe seroconversion.
value changed apparently, and the heterogeneity disappeared ($P = 0.329, I^2 = 13.4\%$). We observed that patients included by Lee et al. [22] had clearly lower mean HBV DNA viral load at baseline than those in the five other studies, which may be the reason for the heterogeneity. Only two included articles had a virological suppression endpoint of 96 weeks, of which one, reported by Seto et al. [19], lacked adequate baseline data, making it difficult to locate the source of heterogeneity.

The limitations of this meta-analysis include the fact that the number of trials meeting the inclusion criteria was small and some studies were not RCTs, with three being retrospective designs. Some studies had small sample sizes and one study had no sufficient baseline information, as mentioned above. In addition, the limited number of studies used in analysis of some endpoints may have weakened the statistical power of the meta-analysis and further undermined the ability to evaluate treatment effects. Some endpoints were observed to suffer from heterogeneity, which may have affected the accuracy of these pooled values. Finally, there was no common detection limit for HBV DNA (three used 69 IU/mL, four used 60 IU/mL, and two used 20 IU/mL), but this situation was difficult to avoid.

In conclusion, based on the available data, our results indicate that TDF-based combination therapy did not show any significant advantage in those efficacy indicators nor did it result in any compromised safety when compared to TDF monotherapy. Further studies are needed to verify this comparison.

**Disclosure**

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the paper.
Conflict of Interests
There is no potential conflict of interests relevant to this paper.

Acknowledgments
This research was supported by the Natural Science Foundation of China (81171560, 81171561); the National Science and Technology Major Project of China (2012ZX10002007001, 2011ZX09302005, and 2012ZX09303001-001); the Key Project of Chongqing Science and Technology (cstc2012gg-yyjs-B10007); the Chongqing Natural Science Commission Foundation (cstc2011jjA10025); and the Medical Research Fund by Chongqing Municipal Health Bureau (2009-1-71).

References
[1] European Association for the Study of the Liver, “EASL Clinical Practice Guidelines: management of chronic hepatitis B,” *Journal of Hepatology*, vol. 50, no. 2, pp. 227–242, 2009.
[2] J. L. Dienstag, “Benefits and risks of nucleoside analog therapy for hepatitis B,” *Hepatology*, vol. 49, no. 5, supplement, pp. S112–S121, 2009.
[3] M. G. Ghany and E. C. Doo, “Antiviral resistance and hepatitis B therapy,” *Hepatology*, vol. 49, supplement 5, pp. S174–S184, 2009.
[4] F. Zoulim and S. Locarnini, “Hepatitis B virus resistance to nucleos(t)ide analogues,” *Gastroenterology*, vol. 137, no. 5, pp. 1593.e2–1608.e2, 2009.
[5] S. J. Patterson, J. George, S. I. Strasser et al., “Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B,” *Gut*, vol. 60, no. 2, pp. 247–254, 2011.
[6] E. J. Heathcote, P. Marcellin, M. Buti et al., “Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B,” *Gastroenterology*, vol. 140, no. 1, pp. 132–143, 2011.
[7] T.-T. Chang, C.-L. Lai, R.-N. Chien et al., “Four years of lamivudine treatment in Chinese patients with chronic hepatitis B,” *Journal of Gastroenterology and Hepatology*, vol. 19, no. 11, pp. 1276–1282, 2004.
[8] S. J. Hadziyannis, N. C. Tassopoulos, E. J. Heathcote et al., “Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years,” *Gastroenterology*, vol. 131, no. 6, pp. 1734–1751, 2006.
[9] Y.-F. Liaw, E. Gane, N. Leung et al., “2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B,” *Gastroenterology*, vol. 136, no. 2, pp. 486–495, 2009.
[10] D. J. Tenney, R. E. Rose, C. J. Baldick, K. A. Pokornowski, B. J. Eggers, J. Fang et al., “Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy,” *Hepatology*, vol. 49, no. 5, pp. 1503–1514, 2009.
[11] R. Zoutendijk, H. L. Zaaijer, T. E. M. S. de Vries-Sluijs et al., “Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV,” *The Journal of Infectious Diseases*, vol. 206, no. 6, pp. 974–980, 2012.
[12] J. Tan, B. Degertekin, S. N. Wong, M. Husain, K. Oberhelman, and A. S. F. Lok, “Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations,” *Journal of Hepatology*, vol. 48, no. 3, pp. 391–398, 2008.
[13] S. P. Hozo, B. Djulbegovic, and I. Hozo, “Estimating the mean and variance from the median, range, and the size of a sample,” *BMJ Medical Research Methodology*, vol. 5, article 13, 2005.
[14] T. Berg, P. Marcellin, F. Zoulim et al., “Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection,” *Gastroenterology*, vol. 139, no. 4, pp. 1207–1217, 2010.
[15] Y.-F. Liaw, L.-S. Sheen, C.-M. Lee et al., “Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease,” *Hepatology*, vol. 53, no. 1, pp. 62–72, 2011.
[16] S. Fung, P. Kwan, M. Fabri et al., “Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B,” *Gastroenterology*, vol. 146, no. 4, pp. 980–988, 2014.
[17] Y. S. Lim, K. S. Byun, B. C. Yoo et al., “Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial,” *Gut*, 2015.
[18] Y. S. Lim, B. C. Yoo, K. S. Byun et al., “Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial,” *Gut*, 2015.
[19] W.-K. Seto, K. Liu, D. K.-H. Wong et al., “Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment,” *Journal of Hepatology*, vol. 59, no. 4, pp. 709–716, 2013.
[20] L. Lu, B. Yip, H. Trinh et al., “Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir,” *Journal of Viral Hepatitis*, vol. 22, no. 8, pp. 675–681, 2015.
[21] K. Choi, H. M. Lee, B. G. Jun et al., “Efficacy of tenofovir-based rescue therapy for patients with drug-resistant chronic hepatitis B,” *Taschan Sobwagi Hakhoe chi*, vol. 65, no. 1, pp. 35–42, 2015.
[22] Y. B. Lee, E. U. Jung, B. H. Kim et al., “Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B,” *Antimicrobial Agents and Chemotherapy*, vol. 59, no. 2, pp. 972–978, 2015.
[23] Y. Liu, Y. Zhang, J. Yuan et al., “Efficacy of tenofovir disoproxil fumarate therapy in Chinese chronic hepatitis B patients after multiple antiviral failures,” *Hepatology Research*, 2014.
[24] O. Keskin, A. Ç. Örmeci, B. Baran et al., “Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B,” *Antiviral Therapy*, vol. 19, no. 6, pp. 543–550, 2014.
[25] S. A. Santos, A. J. UrieI, J. S. Park et al., “Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen,” *European Journal of Gastroenterology & Hepatology*, vol. 18, no. 12, pp. 1247–1253, 2006.
[26] Y. B. Lee, J.-H. Lee, D. H. Lee et al., “Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains,” *Antimicrobial Agents and Chemotherapy*, vol. 58, no. 11, pp. 6710–6716, 2014.
[27] T. Piratsivuth, P. Komolmit, T. Tanwander et al., “52-Week efficacy and safety of tenofovir with conditional tenofovir
intensification at week 24 in HBeAg-positive chronic hepatitis B," *PLoS ONE*, vol. 8, no. 2, Article ID e54279, 2013.

[28] R. F. Schinazi, L. Bassit, M. M. Clayton et al., "Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication," *Antimicrobial Agents and Chemotherapy*, vol. 56, no. 12, pp. 6186–6191, 2012.

[29] A. Snow-Lampart, B. Chappell, M. Curtis et al., "No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus," *Hepatology*, vol. 53, no. 3, pp. 763–773, 2011.

[30] D. M. Gracey, P. Snelling, P. McKenzie, and S. I. Strasser, "Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B mono-infection," *Antiviral Therapy*, vol. 18, no. 7, pp. 945–948, 2013.

[31] S.-N. Si-Ahmed, P. Pradat, R. Zoutendijk et al., "Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study," *Antiviral Research*, vol. 92, no. 1, pp. 90–95, 2011.

[32] M. Toy, F. O. Onder, R. Idilman et al., "The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country," *The European Journal of Health Economics*, vol. 13, no. 5, pp. 663–676, 2012.